Daily non-political popular news in brief.

Patients at risk of adverse events within 3 months after stopping certain ACS therapy

Patients who receive the anti-platelet medication clopidogrel following an acute coronary syndrome (such as heart attack) appear to be at greater risk of a heart attack or death in the first 90 days after stopping clopidogrel treatment, according to a study in the Feb. 6 issue of JAMA.

Read more »

Keywords: patients, risk, adverse, events, months, stopping, certain, acs, therapy, patient, event, month

« Previous | Next »

Similar news on "Patients at risk of adverse events within 3 months after stopping certain ACS therapy":

1. Anti-anginal drug safe but not effective in reducing major cardiac events in ACS patients
   04-24-2007 · EurekAlert!
   The anti-anginal medication ranolazine was shown to be safe in regard to certain outcomes but did not reduce the risk of major cardiovascular events such as death, heart attack or recurrent ischemia following acute coronary syndromes, according to a study in the April 25 issue of JAMA.
   Similar news · Read more »
   
2. Smoking cessation therapy may be harmful for ICU patients
   10-25-2006 · EurekAlert!
   Nicotine replacement therapy, used to help reduce adverse events associated with nicotine withdrawal may actually increase the risk of death for smokers admitted to the intensive care unit, shows a new study presented at CHEST 2006, the 72nd annual international scientific assembly of the American College of Chest Physicians.
   Similar news · Read more »
   
3. Stem cell therapy shows promise in regenerating damaged muscle in heart attack patients
   03-27-2007 · EurekAlert!
   Heart attack patients who received an new intravenous adult stem cell therapy, Provacel, experienced a lower number of adverse events, such as cardiac arrhythmias, and had significant improvements in heart, lung and global function compared to those who received a placebo, according to six-month Phase I study data presented at the American College of Cardiology's Innovation in Intervention: i2 Summit in New Orleans on March 25.
   Similar news · Read more »
   
4. Overcrowded hospitals may risk adverse events on busiest days
   04-23-2007 · EurekAlert!
   Hospitals that operate at or over their capacity may be at increased risk of adverse events that injure patients, according to a study led by investigators from Massachusetts General Hospital and Brigham and Woman's Hospital. The report in the May issue of the journal Medical Care suggests that efforts to meet two primary challenges facing hospitals today -- reducing costs and improving patient safety -- may work against each other.
   Similar news · Read more »
   
5. Angioplasty reduces long-term cardiac risk among heart patients with 'silent' ischemia
   05-08-2007 · EurekAlert!
   When compared with intensive drug therapy, percutaneous coronary intervention (PCI, angioplasty) was more beneficial in reducing the long-term risk of major cardiac events among heart attack survivors with "silent ischemia," according to a study in the May 9 issue of JAMA.
   Similar news · Read more »
   
6. Is your heart aging faster than you are?
   11-26-2007 · EurekAlert!
   Despite the increasing evidence that managing high cholesterol reduces cardiovascular events, many people do not achieve recommended lipid levels. This is due, in part, to patients' lack of understanding about their risk factors and the potential benefits of lifestyle modifications and therapy.
   Similar news · Read more »
   
7. Certain infusion therapy after heart attack does not appear to be beneficial, may cause harm
   11-27-2007 · EurekAlert!
   Infusion of a combination therapy consisting of glucose, insulin, and potassium, which was thought could be a beneficial treatment immediately following a heart attack, may increase the risk of heart failure and death in the first 3 days for patients with ST-segment elevation myocardial infarction, according to a study in the Nov. 28 issue of JAMA.
   Similar news · Read more »
   
8. Sutent achieves first line EAU approval for kidney cancer
   03-22-2007 · EurekAlert!
   Sutent (sunitinib malate) has received a European Association of Urology recommendation, as first-line therapy in patients with metastatic renal cell carcinoma of good and intermediate risk, just two months after gaining EU marketing authorization for first line use in all patients with advanced and/or metastatic renal cell carcinoma.
   Similar news · Read more »
   
9. Molecules might identify high-risk acute-leukemia patients
   01-15-2008 · EurekAlert!
   New research suggests that certain microRNAs might help doctors identify adult acute-leukemia patients who are likely to respond poorly to therapy. The findings showed that both the leukemia cells and their normal counterparts had similar kinds of microRNA, but that the two groups differed in the levels of miRNAs present. The study should improve the understanding of acute myeloid leukemia and could lead to new therapies for patients with few treatment options.
   Similar news · Read more »
   
10. Longer anthracycline therapy reduces heart failure in adult cancer patients
    11-22-2006 · EurekAlert!
    Stretching out a dose of chemotherapy over six or more hours may reduce the risk of heart problems caused by certain commonly used cancer drugs, according to a new review of recent research.
    Similar news · Read more »